Drawing for AGOMAB

USPTO serial 79408296

AGOMAB

Reviewed by CopyMark Law Group

Reg. 7971578Status 700Registered
Filing date
Status date
Registration date
Oct 7, 2025
Examiner
O'BRIEN, JENNIFER LYNN
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with AGOMAB?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Thomas A. Polcyn

Thomas A. Polcyn Thompson Coburn LLPOne US Bank PlazaSt. Louis, MO 63101United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and medical preparations for the treatment of fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; chemical preparations for medical and pharmaceutical purposes, namely, for fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; pharmaceutical and medical preparations for use in relation to treating fibrosis, fibrotic diseases, fibrostenosing Crohn's disease, idiopathic pulmonary fibrosis, skin diseases, eye diseases, organ failure, liver disease, kidney disease, inflammatory disease, degenerative disease, autoimmune disease, and the treatment of diseases requiring tissue repair; small molecule drugs, namely, medicinal preparations for fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repair; antibodies; pharmaceutical and medical preparations incorporating antibodies for the treatment of fibrosis, fibrotic diseases, skin diseases, eye diseases, Lung diseases, Idiopathic pulmonary fibrosis, Interstitial lung disease, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, organ failure, liver disease, kidney disease, inflammatory disease, Inflammatory bowel disease, Crohn's disease, fibrostenosing Crohn's disease, Luminal Crohn's disease, Perianal Crohn's disease, Fistulizing Crohn's disease, ulcerative colitis, Intestinal cancer, Pulmonary arterial hypertension, degenerative disease, autoimmune disease, diseases requiring tissue repairACTIVE—
042Scientific research and development services; Scientific research in the nature of conducting clinical trials for others; research and development in the fields of fibrosis, fibrotic diseases, fibrostenosing Crohn's disease, idiopathic pulmonary fibrosis, skin diseases, eye diseases, organ failure, liver disease, kidney disease, inflammatory disease, degenerative disease, autoimmune disease, and the treatment of diseases requiring tissue repair; research and development in the fields of small molecules and antibodies; research, development and product design of pharmaceutical and medical preparations; pharmaceutical drug development and discovery services; laboratory and medical laboratory product research and development services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy, advisory and information services relating to all the aforesaidACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 30, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 16, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Apr 13, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 13, 2026FIMPFINAL DISPOSITION PROCESSED—
Mar 30, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 29, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jan 7, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 7, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 7, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 3, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Aug 19, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 19, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 13, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 15, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 11, 2025XAECEXAMINER'S AMENDMENT ENTERED—
Jul 11, 2025GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 11, 2025GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 11, 2025CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 3, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 3, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 3, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 24, 2025RFNTREFUSAL PROCESSED BY IB—
May 5, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
May 5, 2025RFRRREFUSAL PROCESSED BY MPU—
Mar 20, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 19, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 17, 2025DOCKASSIGNED TO EXAMINER—
Jan 3, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Nov 4, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 4, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 31, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance